CAMP4 THERAPEUTICS CORPORATION (CAMP) Fair Value 2026

CAMP · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.3 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (33/100)

Quick Summary — As of 2026-08-28, CAMP4 THERAPEUTICS CORPORATION (CAMP) trades at $4.15. QOC: 5.3/10. Value Trap Risk: 33/100 (LOW). 0/13 models active.

Key Facts

Ticker
CAMP
Price
$4.15
Quality Score
5.3/10
Value Trap Risk
33/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give CAMP?

0 Intrinsic Value Models vs. Current Price ($4.15)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, CAMP4 THERAPEUTICS CORPORATION currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About CAMP?

0 of 13 models are currently active for CAMP. See which stocks rank higher →

How Does CAMP Rank in Biotechnology?

Among 625 Biotechnology stocks, CAMP ranks #254 by Quality of Company score. CirclFi's QOC score of 5.3/10 evaluates 32 fundamental signals. A score of 5.3 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, CAMP4 THERAPEUTICS CORPORATION competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is CAMP a Value Trap?

CirclFi's Value Trap algorithm assigns CAMP a score of 33/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for CAMP4 THERAPEUTICS CORPORATION. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, CAMP4 THERAPEUTICS CORPORATION is rated at 5.3/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CAMP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy CAMP4 THERAPEUTICS CORPORATION Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

PROKProKidney Corp.QOC 5.3IFRXInflaRx N.V.QOC 5.3KZIAKazia Therapeutics LimitedQOC 5.3MAZEMaze Therapeutics, Inc.QOC 5.2ICUSeaStar Medical Holding CorporationQOC 5.3GOSSGossamer Bio, Inc.QOC 5.2INABIN8bio, Inc.QOC 4.6HEPAHepion Pharmaceuticals, Inc.QOC 3.6VRDNViridian Therapeutics, Inc.QOC 6.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: PROK · IFRX · KZIA · MAZE · ICU · GOSS · INAB · HEPA · VRDN · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CAMP?

6 companies across all industries closest to CAMP’s Quality of Company score of 5.3/10.

OLBThe OLB Group, Inc.QOC 5.3VWAVVisionWave Holdings, Inc.QOC 5.3UMACUnusual Machines, Inc.QOC 5.3LEENLeopard Energy, Inc.QOC 5.3SGMLSigma Lithium CorporationQOC 5.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: OLB · VWAV · UMAC · LEEN · SGML · NVDA

Where Does CAMP Sit in CirclFi's Biotechnology Rankings?

CAMP is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About CAMP4 THERAPEUTICS CORPORATION’s Valuation?

What is CAMP4 THERAPEUTICS CORPORATION's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for CAMP4 THERAPEUTICS CORPORATION (CAMP). The Quality of Company score is 5.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CAMP overvalued or undervalued right now?

At $4.15, 0 of 0 active models suggest CAMP may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits CAMP4 THERAPEUTICS CORPORATION's business model in Biotechnology.

What does a Quality of Company score of 5.3 mean for CAMP?

CAMP4 THERAPEUTICS CORPORATION's QOC of 5.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CAMP?

CirclFi analyzes CAMP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is CAMP a value trap in 2026?

CAMP4 THERAPEUTICS CORPORATION's Value Trap score is 33/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns CAMP4 THERAPEUTICS CORPORATION (CAMP) a Quality of Company score of 5.3/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CAMP/ · Methodology
Primary sources for this CAMP valuation
  • Financial statements: CAMP4 THERAPEUTICS CORPORATION 10-K and 10-Q filings on SEC EDGAR (CIK 0001736730) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CAMP as of ; valuations recomputed .